EM Device Lab Company Profile

Background

Mission and Vision

EM Device Lab is dedicated to enhancing patient health by providing innovative devices that assist clinicians in delivering more effective and efficient abscess care. The company's vision is to develop unique solutions to real clinical problems, focusing on improving patient outcomes and streamlining medical procedures.

Company History

Founded in 2016 by Dr. Michael Gorn, an emergency medicine physician, EM Device Lab emerged from the recognition of a clinical need in abscess treatment. Dr. Gorn's experience with the "Jacobi Ring" technique for treating Bartholin's abscesses led to the development of the Quickloop Abscess Treatment Device. This device was launched in the U.S. in late 2021 and received an enthusiastic reception from the emergency medicine community.

Key Strategic Focus

Core Objectives and Specialization

EM Device Lab specializes in the development of medical devices aimed at improving abscess treatment procedures. The company's primary objective is to simplify and enhance the loop technique for abscess drainage, thereby reducing treatment failures and patient discomfort.

Key Technologies Utilized

The company's flagship product, the Quickloop Abscess Treatment Device, integrates components and steps of the loop technique into a single device, facilitating a simpler and faster procedure for clinicians. This innovation aims to reduce treatment failures and improve patient satisfaction.

Primary Markets Targeted

EM Device Lab primarily targets the emergency medicine sector, focusing on clinicians involved in abscess care. The Quickloop device is designed to be used in emergency departments and urgent care settings, addressing the needs of healthcare professionals and patients in these environments.

Financials and Funding

Funding History

As a privately held company, EM Device Lab has secured funding through various channels, including grants and non-equity assistance. Notably, the company received support from MassChallenge in October 2020.

Total Funds Raised

Specific details regarding the total funds raised by EM Device Lab are not publicly disclosed.

Notable Investors

While the company has received support from organizations like MassChallenge, detailed information about individual investors is not publicly available.

Utilization of Capital

The capital raised has been utilized for product development, including the creation and launch of the Quickloop Abscess Treatment Device, as well as for operational expenses to support the company's growth and market entry.

Pipeline Development

Key Pipeline Candidates

EM Device Lab's primary focus is on the Quickloop Abscess Treatment Device, which has been developed and launched in the U.S. market. The company is also exploring additional product concepts in various stages of development to address other clinical needs.

Stages of Development

The Quickloop device has completed development and is currently in the market. Other product concepts are in the early stages of development, with timelines for anticipated milestones not publicly disclosed.

Target Conditions

The primary target condition for the Quickloop device is abscesses, particularly those requiring drainage procedures in emergency medicine settings.

Anticipated Milestones

Specific timelines for future product developments and milestones are not publicly available.

Technological Platform and Innovation

Proprietary Technologies

The Quickloop Abscess Treatment Device is EM Device Lab's proprietary technology, designed to streamline the loop technique for abscess drainage. This device integrates all necessary components into a single, user-friendly tool for clinicians.

Significant Scientific Methods

The company employs the loop technique for abscess drainage, which has been shown to reduce treatment failures and improve patient outcomes. The Quickloop device simplifies this technique, making it more accessible and effective for clinicians.

Leadership Team

Key Executives

Dr. Michael Gorn: Founder and Chief Medical Officer. Dr. Gorn is an emergency medicine physician with extensive experience in abscess treatment. He founded EM Device Lab to develop innovative solutions for clinical challenges.

Patrick Kothe: President and CEO. Patrick Kothe has a background in medical device development and has been instrumental in leading EM Device Lab's strategic direction and operations.

Dr. Matt Wilkinson: Chief Clinical Officer. Dr. Wilkinson brings clinical expertise to the company, ensuring that product developments align with the needs of healthcare professionals.

Leadership Changes

As of the latest available information, there have been no significant changes or appointments within the company's leadership team.

Competitor Profile

Market Insights and Dynamics

The medical device industry, particularly in the field of abscess treatment, is characterized by a focus on improving patient outcomes and procedural efficiency. Companies in this sector are continually innovating to provide solutions that address clinical challenges and enhance healthcare delivery.

Competitor Analysis

While specific competitors to EM Device Lab are not publicly detailed, the company operates in a niche market focusing on abscess treatment devices. The competitive landscape includes other medical device companies that develop products for similar clinical applications.

Strategic Collaborations and Partnerships

Significant Collaborations

EM Device Lab has collaborated with organizations like MassChallenge to support its product development and market entry. These partnerships provide resources and mentorship to accelerate the company's growth and innovation.

Operational Insights

Strategic Considerations

EM Device Lab's focus on the Quickloop Abscess Treatment Device positions it uniquely in the market, addressing a specific clinical need with an innovative solution. The company's strategic direction emphasizes product development, market penetration, and establishing a strong presence in the emergency medicine sector.

Strategic Opportunities and Future Directions

Strategic Roadmap

The company's strategic roadmap includes expanding its product portfolio to address additional clinical needs, enhancing the Quickloop device's features based on user feedback, and exploring new markets to broaden its impact.

Future Business Directions

EM Device Lab aims to solidify its position in the abscess treatment market, pursue opportunities for growth through innovation, and continue to develop solutions that improve patient care and clinical efficiency.